Year : 2021 | Volume
: 17 | Issue : 1 | Page : 75--79
Systemic treatment options for growing teratoma syndrome: A single-center experience with a comprehensive review of the literature
Yusuf Acikgoz1, Oznur Bal1, Yakup Ergun1, Berna Oksuzoglu2, Birol Yildiz3, Mutlu Doğan2
1 Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey
2 Department of Medical Oncology, Ankara Dr AY Oncology Training and Research Hospital, Ankara, Turkey
3 Department of Medical Oncology, Elazig City Hospital, Elazig, Turkey
Background: Growing teratoma syndrome (GTS) is a very uncommon phenomena. Given its lower prevalence, there is little data about clinichopathological features and management of GTS. Literature about disease mostly composed of case reports. In this study, we aimed to report patients characteristics and treatment modalities in our center within a relatively large cohort.
Patients and Methods: We retrospectively reviewed the clinical records 21 patients who fulfilled criteria of GTS. Survival analysis was performed by using the Kaplan-Meier method with the Long-rank test. p<0.05 was considered statistically significant.
Results: The median age at diagnosis was 25 (range 17-51). A total of 12 patients could have undergone surgery. Of patients who underwent surgery, 5 patients remained fully disease free, and 7 patients had experienced disease recurrences. Nine patients had unresectable disease, and treated with either platin-based chemotherapy or interferone α2b. Of those, 5 patients eventually had undergone autologous stem cell transplantation (ASCT) with surprisingly promising response rates. One patient had complete response and three patients had partial response. One patient died soon after ASCT due to infectious complication.
Conclusion: GTS is an unique entity with regard to its clinicopathological features and available treatment options as we mentioned in the text. Despite various agents reported to have efficacy in case reports, surgery remains as the mainstay of treatment. According to result of our study, ASCT and platin-based chemotherapy regimens may be feasible options for patients with unresectable disease.
Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara 06100
|How to cite this article:|
Acikgoz Y, Bal O, Ergun Y, Oksuzoglu B, Yildiz B, Doğan M. Systemic treatment options for growing teratoma syndrome: A single-center experience with a comprehensive review of the literature.J Can Res Ther 2021;17:75-79
|How to cite this URL:|
Acikgoz Y, Bal O, Ergun Y, Oksuzoglu B, Yildiz B, Doğan M. Systemic treatment options for growing teratoma syndrome: A single-center experience with a comprehensive review of the literature. J Can Res Ther [serial online] 2021 [cited 2022 Jan 24 ];17:75-79
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2021;volume=17;issue=1;spage=75;epage=79;aulast=Acikgoz;type=0